GEN1047 (Genmab)

GEN1047 is a bispecific antibody developed by Genmab using its proprietary DuoBody technology platform. It is designed to simultaneously target CD47, an immune checkpoint that provides a "don't eat me" signal to macrophages, and EpCAM (Epithelial Cell Adhesion Molecule), a cell surface antigen frequently overexpressed in various carcinomas. By dual-targeting, GEN1047 aims to selectively block the CD47-SIRPα interaction on EpCAM-positive tumor cells, thereby promoting macrophage-mediated phagocytosis of malignant cells while minimizing off-target binding to CD47 on healthy tissues, such as red blood cells. This approach is intended to enhance the therapeutic index and reduce the hemotoxicity typically associated with systemic CD47 blockade. GEN1047 is currently undergoing early-phase clinical evaluation for the treatment of advanced solid tumors, including breast, endometrial, ovarian, and squamous non-small cell lung cancers.

Other names

DuoBody-CD47xEpCAMDuoBody-CD-47xEpCAMDuoBody-CD 47xEpCAMCD47 x EpCAM bispecific antibodyCD-47 x EpCAM bispecific antibodyCD 47 x EpCAM bispecific antibody